Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies.
The last earnings update was 49 days ago.
Discounted Cash Flow Calculation for DB:5TA using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:5TA DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Aimmune Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
Aimmune Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Aimmune Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Aimmune Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Aimmune Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Aimmune Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Aimmune Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Aimmune Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aimmune Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Aimmune Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 4007.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Jayson Donald Alexander Dallas, M.D. has been President, Chief Executive Officer and Director of Aimmune Therapeutics, Inc. since June 19, 2018. He served as the Chief Commercial Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc. since August 3, 2015 until June 18, 2018 and from January 2016 to June 18, 2018 respectively. Dr. Dallas commenced employment with Ultragenyx in August 2015. He served as Senior Vice President at Ultragenyx since August 3, 2015 until January 2016. He served as General Manager of Roche in the United Kingdom from July 2012 to July 2015. Prior to this, at Genentech, he held two different positions as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology from May 2010 to June 2012. Prior to Genentech, he worked at Novartis and Pharmacia in the US and previously at Roche in Switzerland. Over the course of his 21 year career in the industry, he has successfully overseen multiple product launches, internationally and in the US and has led numerous commercial organizations through periods of rapid growth. He worked in various medical functions within the industry and also as a practicing clinician. He has been an Independent Director of Arena Pharmaceuticals, Inc. since February 14, 2017. Dr. Dallas holds an MD from the University of the Witwatersrand, Johannesburg, South Africa and an MBA from Ashridge Business School in the United Kingdom.
Insufficient data for Jayson Donald to compare compensation growth.
Insufficient data for Jayson Donald to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Aimmune Therapeutics management team is about average.
Chief Financial Officer
Chief Operating Officer
General Counsel & Secretary
Chief Medical Officer
Jayson Donald Dallas
Vice President of Investor Relations
Vice President of Community and Public Affairs
Senior Vice President of Corporate & Strategy Development
Senior Vice President of Global Regulatory Affairs & Quality Assurance
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Aimmune Therapeutics board of directors is about average.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow’s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.